skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Buparlisib (Code C90565)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Buparlisib

Definition: An orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases with potential antineoplastic activity. Buparlisib specifically inhibits class I PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway in an ATP-competitive manner, thereby inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate and activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.

Display Name: Buparlisib

Label: Buparlisib

NCI Thesaurus Code: C90565 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C3886769  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
BKM120
Buparlisib
PI3K Inhibitor BKM120

External Source Codes: 
PDQ Closed Trial Search ID 667281
PDQ Open Trial Search ID 667281 (check for NCI PDQ open clinical trial info)
UMLS CUI C3886769

Other Properties:
     Name Value (qualifiers indented underneath)
code C90565
Contributing_Source CTRP
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  

URL: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C90565

Mainbox Bottom